Participants 42 93 4
secondary hyperparathyroidism in stages 3 and 4 CKD
Participants 260 310 5
patients with chronic kidney disease (CKD) stage 5
Participants 441 554 4
Three randomized, placebo-controlled, phase-3 trials were conducted in patients with stages 3 and 4 CKD with SHPT
Participants 1243 1325 3
Two hundred twenty patients participated (n = 107, paricalcitol; n = 113, placebo)
